Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br PERSPECTIVES br COMPETENCY IN PATIENT CARE AND PROCEDURAL

    2020-08-28


    PERSPECTIVES
    COMPETENCY IN PATIENT CARE AND PROCEDURAL OUTCOMES: Despite the competing risks of cancer-related death, patients with locally advanced NSCLC may benefit from reduction of cardiac radiation dose, preventive post-radiotherapy cardiac care, and earlier recognition and treatment of cardiovascular events.
    TRANSLATIONAL OUTLOOK: Prospective studies are needed to assess the effect of combined cardiac risk stratification, Taurochenodeoxycholic acid cardiac radiation dose reduction techniques, and post-radiotherapy preventive care on survival and quality of life in patients with lung cancer.
    2. van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary Taurochenodeoxycholic acid disease in survivors of Hodgkin lymphoma. J Clin Oncol 2016;34:235–43.
    5. Schytte T, Hansen O, Stolberg-Rohr T, Brink C. Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer. Acta Oncol 2010;49:1058–60.
    6. Hardy D, Liu CC, Cormier JN, Xia R, Du XL. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol 2010;21:1825–33.
    7. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16:187–99.
    8. Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin 
    or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2016;34:953–62.
    10. Aberle DR, Adams AM, Berg CD, et al., for the National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395–409.
    12. Wang K, Eblan MJ, Deal AM, et al. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol 2017;35:1387–94.
    13. Dess RT, Sun Y, Matuszak MM, et al. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol 2017;35:1395–402.
    14. Speirs CK, DeWees TA, Rehman S, et al. Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer. J Thorac Oncol 2017;12:293–301.
    15. Tucker SL, Liu A, Gomez D, et al. Impact of heart and lung dose on early survival in patients 
    16. Guberina M, Eberhardt W, Stuschke M, et al. Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial. Ann Oncol 2017;28:1084–9.
    17. Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Nucl Cardiol 2015;22:1041–144.
    19. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic car-diovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Car-diol 2014;63:2889–934.
    21. Feng M, Moran JM, Koelling T, et al. Devel-opment and validation of a heart atlas to study
    cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011;79:10–8.
    22. Hicks KA, Tcheng JE, Bozkurt B, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol 2015;66:403–69.
    23. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc 1993;88:400–9.
    25. Schoenfeld D. Chi-squared goodness-of-fit tests for the proportional hazards regression model. Biometrika 1980;67:145–53.
    29. Lu MT, Onuma OK, Massaro JM, D’Agostino RB Sr., O’Donnell CJ, Hoffmann U. Lung cancer screening eligibility in the community: cardiovascular risk factors, coronary artery calci-fication, and cardiovascular events. Circulation 2016;134:897–9.